NYSE:OSCR 3 October 2025 - 10 February 2026

Oscar Health shares rose 3.3% to $12.66 in premarket trading after forecasting 2026 revenue of $18.7–$19.0 billion and operating earnings of $250–$450 million. The company posted a wider Q4 net loss of $353 million and a medical loss ratio of 95.4%. A U.S. House panel subpoenaed Oscar and other insurers over ACA subsidy practices. Oscar also disclosed a new $475 million revolving credit facility.

Oscar Health shares traded near $16.63 on December 15, 2025, as the ACA open enrollment deadline coincided with new analyst coverage and policy debate in Washington. Congress is weighing the fate of enhanced ACA premium tax credits set to expire at the end of 2025. KFF projects average subsidized premiums could more than double in 2026 if subsidies lapse. Oscar’s business is heavily exposed to these ACA marketplace shifts.

Oscar Health shares traded near $15.80 on Thursday after closing at $15.59, down 8% despite broader market gains. Stephens & Co. initiated coverage with an “Equal-Weight” rating and a $17 price target. Analyst targets now range from $11 to $25, with volatility metrics remaining elevated. The stock’s 52-week range is $11.20 to $23.80, and market cap stands at about $4.1 billion.

Oscar Health shares surged 35% on speculation of extended ACA subsidies, then fell amid analyst downgrades and increased bearish options activity. The stock closed at $16.77, about 30% below its 52-week high. Q3 revenue rose 23% to $3 billion, but net loss widened to $137 million. Membership reached 2.12 million, up from 1.65 million a year ago.

Oscar Health closed at $22.30 on Oct. 6, 2025, with a market cap near $5.6 billion after surging 42% year-to-date. Q2 revenue rose 29% to $2.86 billion, but the company posted a $228 million net loss as its medical loss ratio jumped to 91.1%. Membership topped 2 million. Wall Street consensus remains “Strong Sell,” with an average 12-month price target of $12.

Oscar Health shares traded near $19.81 midday Oct. 3, up about 2.8%, with a market cap around $4.9 billion. The company reported Q2 revenue of $2.86 billion and a $228 million net loss, serving about 2 million members, mostly in ACA exchanges. On Sep. 11, Oscar announced a $350 million convertible note offering to fund growth and retire its credit line. Analyst ratings remain cautious, with recent downgrades citing ACA risk.